

## Disclosures

### Personal Commercial (8)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Amgen Inc.	Research/Research Grants	Significant (>= \$5,000)	<a href="#">Prevention</a>
Eli Lilly and Company	Research/Research Grants	Modest (< \$5,000)	<a href="#">Prevention</a>
Kaneka	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Prevention</a>
Kaneka	Research/Research Grants	Significant (>= \$5,000)	<a href="#">Prevention</a>
New Amsterdam	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Prevention</a>
Novartis	Research/Research Grants	None (\$0)	<a href="#">Prevention</a>
Novartis Corporation	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Prevention</a>
Novo Nordisk Inc.	Research/Research Grants	Significant (>= \$5,000)	<a href="#">Prevention</a>

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (1)

Year	Case Title	Represented	Description	Compensation
<i>Self</i>				
2024	Coronary artery disease testing	Defendant	Patient with CAC who underwent coronary angiogram and suffered a complication of the procedure.	Significant (>= \$5,000)

† Commercial Funding Source | ‡ Trial Name

## Agreement

### Certified Education Attestation | Signed on 12/10/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

### Confidentiality, Disclosure and Assignment Agreement | Signed on 12/10/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

### Embargo | Signed on 12/10/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

### On-Going Obligation Agreement | Signed on 12/10/2024

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members

involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.